Showing 3881-3890 of 4107 results for "".
- SkinMedica Unveils Hydroquinone-Free Skin Brightening Complexhttps://practicaldermatology.com/news/20130314-skinmedica_unveils_hydroquinone-free_skin_brightening_complex/2459588/SkinMedica introduced its new skin brightening product, SkinMedica Lytera™ Skin Brightening Complex, a hydroquinone-free product that reduces the appearance of skin discoloration and dark spots. Featuring a proprietary blend of ingredients, SkinMedica Lytera™ Skin Brightening Complex works to bright
- NeoStrata Introduces Line Lift Duohttps://practicaldermatology.com/news/20130314-neostrata_introduces_line_lift_duo/2459589/NeoStrata Company, Inc. launched the SKIN ACTIVE Line Lift featuring Aminofil™, a novel tyrosine amino acid derivative (N-Acetyl Tyrosinamide) that delivers a rapid volumizing effect in the deep skin matrix to visibly reduce deep facial lines and wrinkles. Applied together twice daily, the SKIN ACTI
- PhotoMedex Launches Three New Neova Productshttps://practicaldermatology.com/news/20130311-photomedex_launches_three_new_neova_products/2459594/Three new Neova products are now available from PhotoMedex. The first is Serious Clarity 4X, an advanced serum with four highly effective brighteners that reverse the appearances of dark spots and skin discolorations. Also available is Illuminating Eye Therapy 4.0, which is designed to combat dark c
- Envy Medical Unveils New Acne Systemhttps://practicaldermatology.com/news/20130311-envy_medical_unveils_new_acne_system/2459595/Envy Medical Inc. recently launched the ClarityMD Acne Solution at the American Academy of Dermatology Annual Meeting on March 1 in Miami. The system includes a Deep Pore Cleanser and Clarifying Gel in a two-step system that's clinically proven to significantly heal acne within days, according to th
- Apremilast Phase III Results Show Efficacy Over Time for Psoriasishttps://practicaldermatology.com/news/20130311-apremilast_phase_iii_results_show_efficacy_over_time_for_psoriasis/2459597/Results from a new Phase III study presented at the AAD Meeting in Miami demonstrate the efficacy of the oral molecule apremilast (Celgene) in psoriasis patients. The ESTEEM 1 study evaluated efficacy and safety in a range of patients, approximately one-third of which was systemic and/or phototherap
- Valeant Launches Acne Scholarship Programhttps://practicaldermatology.com/news/20130311-valeant_launches_acne_scholarship_program/2459598/Valeant Dermatology recently launched a scholarship program entitled, Acanya® I Can Succeed, an initiative that will provide college scholarship money to students who have had acne and have actively tried to address it. The Acanya I Can Succeed Scholarship program will award a total of up to $48,000
- PreCision Dermatology Appoints Chief Operating Officerhttps://practicaldermatology.com/news/20130307-precision_dermatology_appoints_chief_operating_officer/2459601/Robert Moccia has been appointed to the newly created position of Chief Operating Officer of PreCision Dermatology, Inc. In that role, all operating functions of PreCision will report to Mr. Moccia. In addition, Mr Moccia will serve as the President of Onset Dermatologics, LLC, a wholly owned subsid
- Alma Lasers to Present New Technologies at AAD Meetinghttps://practicaldermatology.com/news/20130227-alma_lasers_to_present_new_technologies_at_aad_meeting/2459604/Alma Lasers unveiled its two latest technologies, the vShape focused radiofrequency (RF) workstation and the ClearLift. The RF workstation addresses tailored anti-aging treatments for the face, body, and cellulite. The ClearLift is Q-switched technology penetrates deep beneath the skin and decreases
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treat
- Epiduo Approved For Patients as Young as 9-Years-Oldhttps://practicaldermatology.com/news/20130219-epiduo_approved_to_treat_acne_in_patients_as_young_as_nine_years_old/2459612/Based on the results of a recent clinical study in pediatric patients, the FDA has approved Epiduo (adapalene 0.1%/BPO 2.5%, Galderma) Gel to treat acne in children as young as nine years old. In the 12-week multicenter, randomized, vehicle-controlled, double-blind study, investigators evaluated the